Sumary of BioNTech to seek approval in a 'few weeks' for Covid vaccine for children as young as 5:
- FRANKFURT — BioNTech is set to request approval across the globe to use its Covid-19 vaccine in children as young as five over the next few weeks and preparations for a launch are on track, the biotech firm’s two top executives told Der Spiegel.
- “Already over the next few weeks we will file the results of our trial in five to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told the German news weekly.
- RelatedTuereci also told Spiegel that final production steps were being adjusted to bottle a lower-dose pediatric version of its established Comirnaty vaccine.
- The raw trial data was now being prepared for a regulatory filing and “things are looking good, everything is going according to plan”, Chief Executive Ugur Sahin told Der Spiegel.